Brokerages forecast that Voyager Therapeutics Inc (NASDAQ:VYGR) will post $5.05 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Voyager Therapeutics’ earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $6.71 million. Voyager Therapeutics posted sales of $2.36 million in the same quarter last year, which suggests a positive year-over-year growth rate of 114%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $5.05 million for the current financial year, with estimates ranging from $4.70 million to $10.49 million. For the next fiscal year, analysts anticipate that the company will report sales of $13.24 million per share, with estimates ranging from $5.00 million to $32.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Thursday, November 2nd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.17). Voyager Therapeutics had a negative net margin of 1,195.63% and a negative return on equity of 65.50%.
In other news, insider Bernard Ravina sold 5,490 shares of the firm’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $13.63, for a total transaction of $74,828.70. Following the completion of the sale, the insider now directly owns 10,983 shares of the company’s stock, valued at approximately $149,698.29. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 14,610 shares of company stock valued at $207,158. Corporate insiders own 8.00% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its position in shares of Voyager Therapeutics by 312.8% in the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock worth $7,766,000 after buying an additional 285,806 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Voyager Therapeutics by 20.9% during the second quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock worth $477,000 after acquiring an additional 9,207 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Voyager Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after acquiring an additional 13,194 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter worth $5,155,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Voyager Therapeutics during the third quarter worth $2,695,000. 36.01% of the stock is owned by institutional investors and hedge funds.
Shares of Voyager Therapeutics (NASDAQ VYGR) opened at $20.23 on Tuesday. Voyager Therapeutics has a 1 year low of $8.10 and a 1 year high of $25.99. The company has a market capitalization of $545.19 and a P/E ratio of -7.12.
ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/23/voyager-therapeutics-inc-vygr-expected-to-announce-quarterly-sales-of-5-05-million.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.